Current clinical applications of ccfDNA-based analysis encompass treatment guidance in non-small cell lung cancer (NSCLC) through identification of, e.g., EGFR, BRAF, and KRAS mutations both at primary diagnosis [3] and progression upon treatment resistance [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.